Is bifrontal electroconvulsive therapy safe in a patient receiving Invega Sustenna (paliperidone palmitate) and cariprazine, and what precautions are needed?

Bifrontal ECT with Invega Sustenna and Cariprazine: Safety and Management

Bifrontal ECT can be safely administered to patients receiving Invega Sustenna (paliperidone palmitate) and cariprazine, as atypical antipsychotics do not represent a contraindication to ECT and should be continued throughout treatment. 1

Key Safety Principle

Continue both atypical antipsychotics during ECT – Unlike lithium, benzodiazepines, carbamazepine, trazodone, and theophylline, which must be discontinued, atypical antipsychotics including paliperidone palmitate and cariprazine can and should be maintained throughout the entire ECT course. 1, 2 The American Academy of Child and Adolescent Psychiatry confirms no absolute contraindication exists for ECT in patients taking antipsychotics. 3, 1

Pre-ECT Medication Review

Before initiating bifrontal ECT, conduct a comprehensive medication audit focusing on high-risk agents that interfere with seizure induction or prolong seizure activity:

Medications That MUST Be Discontinued 1, 2:

• Lithium – Risk of acute cerebral syndrome when combined with ECT 1, 2
• Benzodiazepines – Elevate seizure threshold, preventing adequate therapeutic seizures 1, 2
• Carbamazepine – Associated with failure to induce seizures during ECT 1, 2
• Trazodone – Linked to prolonged seizures during ECT 1, 2
• Theophylline – Prolongs seizure duration at both therapeutic and toxic concentrations 1, 2

Medications to CONTINUE 1, 4:

• Invega Sustenna (paliperidone palmitate) – Safe throughout ECT; may enhance treatment tolerability 1
• Cariprazine – Safe throughout ECT; no problematic anticonvulsant properties 1
• Other atypical antipsychotics (olanzapine, mirtazapine) – Recommended as part of maintenance strategy 4

Intra-ECT Monitoring Protocol

During Each ECT Session 1:

• Monitor for increased sedation or somnolence attributable to the combined effects of atypical antipsychotics and anesthesia 1, 4
• Watch for orthostatic hypotension, particularly with concurrent antipsychotic use 4
• Assess seizure duration using simultaneous EEG recording or the cuff method 3
• Identify prolonged seizures (>180 seconds on EEG) – occurs in 0-10% of treatments and requires immediate termination with additional methohexital, diazepam, or lorazepam 3, 1, 2

Immediate Post-Treatment (1-2 hours) 3:

• Observe in designated ECT recovery area with nurse skilled in unconscious patient care 3
• Monitor vital signs, airway patency, and adverse events 3
• Have resources available for managing agitation or seizures 3
• Treat headaches with acetaminophen 3
• Watch for manic/hypomanic symptoms during recovery period 3

Post-ECT Surveillance

24-48 hour monitoring window – All patients require surveillance for tardive seizures (late-onset seizures occurring after full recovery from anesthesia). 3, 1, 2 This is critical as tardive seizures represent a rare but serious complication requiring neurological consultation. 2

Common Pitfalls to Avoid

Critical Distinction 1:

Do NOT confuse atypical antipsychotics with anticonvulsants – While carbamazepine and valproate (anticonvulsants) must be stopped before ECT, atypical antipsychotics like paliperidone and cariprazine lack problematic anticonvulsant properties and should be maintained. 1

Medication Management Errors 1, 2:

• Never discontinue atypical antipsychotics – This is a common error; these agents are safe and beneficial during ECT 1
• Prioritize stopping high-risk agents first – Focus discontinuation efforts on lithium, trazodone, carbamazepine, theophylline, and benzodiazepines 1, 2
• If high-risk drugs cannot be stopped due to clinical necessity, continue them only with enhanced monitoring protocols 1, 2

Special Considerations for Paliperidone Palmitate

Given that Invega Sustenna is a long-acting injectable formulation, note that:

• Plasma levels persist for extended periods after discontinuation, making abrupt cessation impractical 5
• Gender-specific monitoring may be warranted: females are more prone to hyperprolactinemia and weight gain, while males experience higher rates of sexual dysfunction 5
• Common ADEs include elevated prolactin, galactorrhea, and psychosexual disorders, though these do not contraindicate ECT 5

Management of Complications

If Prolonged Seizures Occur 3, 1, 2:

1. Administer additional methohexital, diazepam, or lorazepam immediately 3, 1
2. Recurrent prolonged seizures may herald tardive seizures 3
3. Obtain neurological consultation before considering further ECT 3, 2

If Manic Symptoms Emerge During Recovery 3:

• Consider changing electrode placement (e.g., from unilateral to bilateral) 3
• Continue treatment until symptom resolution is achieved 3

Physical Examination Requirements

Before initiating ECT, complete the following baseline assessments 3:

• Complete physical examination 3
• Complete blood count with differential 3
• Electrolyte panel 3
• Liver and thyroid function tests 3
• Urinalysis and toxicology screen 3
• Electrocardiogram 3
• Pregnancy test for females 3
• Consider MRI or CT scan if structural CNS abnormalities are suspected 3

No absolute medical contraindications exist for ECT, though relative contraindications require identification and management. 3 The primary risks are those associated with brief general anesthesia. 3